Surya Pharmaceutical, a Chandigarh-based pharmaceutical company, has marked impressive financial performance during the fourth quarter ended March 2008. Its net profit has taken a quantum jump of 56.5 per cent and touched to Rs 12.79 crore from Rs 8.17 crore in the corresponding period of last year. Its net sales went up sharply by 91 per cent to Rs 156.48 crore from Rs 82.11 crore. The earning per share significantly improved to Rs 8.84 from Rs 5.64 in the last period.

For the full year ended March 2008, Surya Pharma has notched up a net profit growth of 97.3 per cent to Rs 46.74 crore from Rs 23.69 crore. Similarly its net sales touched to Rs 496.67 crore as against Rs 283.40 crore, representing a growth of 75.3 per cent. The annual earning per share reached at Rs 34.81 from Rs 17.64 in the previous year.

The company has four manufacturing facilities in three northern states of India viz. Two in industrial township Baddi (Himachal Pradesh Province), one in Industrial area of Panchkula(Haryana Province) and one in Banur (Punjab Province). All three provinces are nearby and bordering Chandigarh, where corporate office is located. Another state of art unit is to be commissioned shortly at Sambha(J&K). The company and its manufacturing units are ISO 9001-2000 certified by international accredition agency.

All the facilities are under up gradation for US FDA/ European regulatory compliance.

Banur facility has been approved by Ranbaxy & Glaxo. The Panchkula facility is approved by DAI and the Baddi formulation facility is approved by Cipla, Wockhardt, Helm AG, German Remedies and Elder. The API unit at Baddi has been approved by Ranbaxy.